SAIPARENT
Sai Parenterals financials
- Market cap
- ₹2.4k Cr
- Sector
- Healthcare
- Calls analysed
- 2
Sai Parenterals Limited Q1 FY27
What went well
- Consolidated gross margin expanded by 370 bps to 41.8% from 38.1% in the preceding quarter.
- Consolidated EBITDA margin expanded by 50 bps to 14.9% from 14.4% in the preceding quarter.
- Strategic acquisition of 60% equity in Saicriti Pharma Private Limited for Rs. 83.83 crores to establish an EU-GMP/USFDA compliant injectable facility, increasing capacity by 47% and adding a domestic critical care franchise of Rs. 52 crores.
What to watch
- Consolidated total revenue declined to Rs. 182 crores from Rs. 201 crores in Q4 FY26.
- Consolidated Profit After Tax (PAT) declined to Rs. 8 crores from Rs. 13.2 crores in Q4 FY26.
What Sai Parenterals Limited does
Sai Parenterals is a Hyderabad-headquartered pharmaceutical formulations company that develops, manufactures and exports branded generics and provides contract development and manufacturing (CDMO) services to regulated and semi-regulated markets. It operates four manufacturing units in Telangana focused on sterile injectables, cephalosporin and general oral dosage forms, plus a fifth unit, Revat Laboratories in Ongole, Andhra Pradesh, for domestic branded generics. In November 2025 it acquired a 74.6% stake in Australia's Noumed Pharmaceuticals, adding CDMO manufacturing and market access in Australia and New Zealand, with a new facility under construction in Adelaide. Revenue comes from domestic branded formulation sales and long-term CDMO supply contracts with customers in regulated export markets.
Segments
- Branded Generic Formulations
- CDMO (Contract Development & Manufacturing)
- Manufacturing facilities
- 6 (Units I-IV in Telangana; Revat Laboratories in Ongole, Andhra Pradesh; Noumed facility under construction in Adelaide, Australia)
- Product portfolio
- 302 complex products across critical therapeutic areas
- Approved product registrations in regulated markets
- 599 (456 with TGA-Australia; 143 across other countries)
- Product dossiers under development
- 67
- Installed capacity - India injectable/oral-dosage units
- Unit I: 42 million units/yr; Unit II: 15 million; Unit III: 240 million; Unit IV: 293 million
- Installed capacity - Revat Laboratories (Ongole)
- 570 million units/year
Guidance record · Q1 FY27
what the last two calls moved 12 tracked 0 delivered 1 missed 11 open- Working Capital as % of Additional Revenue went quiet said Q4 FY26 Promised: About 25% to 30% of additional revenues as the working capital requirement. Q1 FY27: This guidance was not mentioned or updated in the Q1 FY27 earnings call.
- Noumed Australian Facility Operational Status delayed said Q4 FY26 Promised: Australian manufacturing facility becomes operational in Q4 FY '27 Q1 FY27: The timeline has been clarified: physical completion is targeted for January 2027, but Phase 1 manufacturing is now expected from April 2027, which is Q1 FY28. This marks a slight delay from the original 'operational in Q4 FY27' guidance.
- FY27 Consolidated Revenue on track said Q4 FY26 Promised: INR750 crores for the financial year '27 Q1 FY27: Management reiterated the full-year guidance of Rs. 750 crores in revenue for FY27. Q1 revenue of Rs. 182 crores represents 24% of the target, which management states is ahead of schedule given an expected 45:55 H1:H2 revenue split.
All 12 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 435.1%, net profit up 457.7% against the same quarter last year.
| Line item | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|
| Revenue | 33 | 87 | 96 | 198 | 179 +435% |
| EBITDA | 5 | 16 | -4 | 26 | 24 +396% |
| Net profit | 1 | 8 | -7 | 13 | 8 +458% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +29.0% YTD
YTD: ₹405.7 on 2 Apr 2026 → ₹523.35. High ₹623.8 (2 Jul 2026), low ₹405.7 (2 Apr 2026).
How the price took the results
close before → close after
- Q1 FY27
- −3.7%
- 12 Aug
- Q4 FY26
- +0.2%
- 27 May
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
| Year ending | FY26 |
|---|---|
| Revenue | ₹414 Cr |
| Operating profit | ₹43 Cr |
| Operating margin | 10.4% |
| Interest | ₹21 Cr |
| Depreciation | ₹18 Cr |
| Net profit | ₹16 Cr |
| Net margin | 3.8% |
| Cash from operations | ₹93 Cr |
| Free cash flow | ₹-184 Cr |
| ROCE | 5.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Equity capital | ₹7 Cr | ₹13 Cr | ₹18 Cr | ₹22 Cr |
| Reserves | ₹24 Cr | ₹61 Cr | ₹189 Cr | ₹469 Cr |
| Borrowings | ₹69 Cr | ₹119 Cr | ₹78 Cr | ₹469 Cr |
| Other liabilities | ₹34 Cr | ₹75 Cr | ₹91 Cr | ₹465 Cr |
| Total liabilities | ₹134 Cr | ₹268 Cr | ₹376 Cr | ₹1.4k Cr |
| Fixed assets | ₹44 Cr | ₹70 Cr | ₹55 Cr | ₹364 Cr |
| Capital work in progress | ₹2 Cr | ₹0 Cr | ₹2 Cr | ₹212 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹88 Cr | ₹198 Cr | ₹320 Cr | ₹848 Cr |
| Total assets | ₹134 Cr | ₹268 Cr | ₹376 Cr | ₹1.4k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Mar 2026, the public added +6.04 pp while DIIs trimmed −4.34 pp. The shareholder count grew 21% to 9,312.
- Promoters
- 51.2%
- FIIs
- 4.0%
- DIIs
- 8.5%
- Public
- 36.3%
Since Mar 2026
- Public +6.04 pp
- DIIs −4.34 pp
- FIIs −1.70 pp
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Bhaskara Rao Bollineni +1.66 pp 4.56% held
- Arihant Capital Markets Limited newly disclosed 1.39% held
- India Emerging Giants Fund Limited FPI fund newly disclosed 1.33% held
- Morgan Stanley Asia (Singapore) Pte. - Odi Foreign bank / ODI newly disclosed 1.17% held
The same filing shows 1 holder trimming and 3 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Sai Parenterals Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Vijitha Gorrepati | 28.91% | unchanged |
| Anil Kumar Karusala | 10.32% | unchanged |
| Aruna Karusala | 7.40% | unchanged |
| Bhaskara Rao Bollineni | 4.56% | +1.66 pp |
| Kunal Kakumanu | 4.53% | unchanged |
| Samarsh Capital-Samarsh Capital-Fund I AIF | 3.45% | unchanged |
| Kotak Mahindra Life Insurance Company Ltd Insurer | 2.35% | −0.54 pp |
| Aig Direct Llc | 2.12% | unchanged |
| Agilis Partners Llp | 2.06% | unchanged |
| Kotak Life Sciences Fund I Mutual fund | 1.73% | unchanged |
| Nanda Govind Bhattad | 1.66% | unchanged |
| Reina R Jaisinghani | 1.59% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
All earnings calls (2)
Read the Q1 FY27 call →Learn to analyse Sai Parenterals Limited
Guides on how to read this kind of business and the numbers that matter.